Selected article for: "human antibody and phage display"
Author: Cao, Xia; Maruyama, Junki; Zhou, Heyue; Kerwin, Lisa; Sattler, Rachel; Manning, John T.; Johnson, Sachi; Richards, Susan; Li, Yan; Shen, Weiqun; Blair, Benjamin; Du, Na; Morais, Kyndal; Lawrence, Kate; Lu, Lucy; Pai, Chin-I; Li, Donghui; Brunswick, Mark; Zhang, Yanliang; Ji, Henry; Paessler, Slobodan; Allen, Robert D.
Title: Discovery and Development of Human SARS-CoV-2 Neutralizing Antibodies using an Unbiased Phage Display Library Approach
  • Cord-id: cpiveo7j
  • Document date: 2020_9_29
    • ID: cpiveo7j
    Snippet: SARS-CoV-2 neutralizing antibodies represent an important component of the ongoing search for effective treatment of and protection against COVID-19. We report here on the use of a naïve phage display antibody library to identify a panel of fully human SARS-CoV-2 neutralizing antibodies. Following functional profiling in vitro against an early pandemic isolate as well as a recently emerged isolate bearing the D614G Spike mutation, the clinical candidate antibody, STI-1499, and the affinity-engi
    Document: SARS-CoV-2 neutralizing antibodies represent an important component of the ongoing search for effective treatment of and protection against COVID-19. We report here on the use of a naïve phage display antibody library to identify a panel of fully human SARS-CoV-2 neutralizing antibodies. Following functional profiling in vitro against an early pandemic isolate as well as a recently emerged isolate bearing the D614G Spike mutation, the clinical candidate antibody, STI-1499, and the affinity-engineered variant, STI-2020, were evaluated for in vivo efficacy in the Syrian golden hamster model of COVID-19. Both antibodies demonstrated potent protection against the pathogenic effects of the disease and a dose-dependent reduction of virus load in the lungs, reaching undetectable levels following a single dose of 500 micrograms of STI-2020. These data support continued development of these antibodies as therapeutics against COVID-19 and future use of this approach to address novel emerging pandemic disease threats.

    Search related documents:
    Co phrase search for related documents
    • acute respiratory disease syndrome and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory disease syndrome and lung titer: 1, 2
    • acute respiratory disease syndrome and lung virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory disease syndrome and lung virus titer: 1
    • acute respiratory disease syndrome coronavirus and ade antibody dependent enhancement: 1, 2, 3, 4, 5, 6
    • acute respiratory disease syndrome coronavirus and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory disease syndrome coronavirus and lung titer: 1
    • acute respiratory disease syndrome coronavirus and lung virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory disease syndrome coronavirus and lung virus titer: 1
    • ade antibody dependent enhancement and lung tissue: 1
    • ade antibody dependent enhancement and lung virus: 1